Clinical Trial Results:
A Phase 1b/2, open-label dose escalation with expansion study of GB5121 in adult patients with relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphoma, with a Phase 2 open-label single dose level study of GB5121 in adult patients with relapsed/refractory primary central nervous system lymphoma
Summary
|
|
EudraCT number |
2021-006234-39 |
Trial protocol |
ES IT NL SE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Mar 2024
|
First version publication date |
06 Mar 2024
|
Other versions |
|
Summary report(s) |
GB5121-2101 summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.